The MAP Congress is a unique and highly influential meeting driving the essential integration into daily practice of information derived from the analysis of tumour samples.
Established by Jean-Charles Soria, Fabrice André and Charles Swanton, the MAP Congress, a very dynamic, interactive forum, has become a must-attend meeting for specialists working in precision medicine in oncology. The Congress explores all options for patients based on the genomic information obtained through the sequencing of all tumours and the tumour microenvironment. The Congress programme remains at the cutting edge of new developments including the latest findings in immunotherapy.
MAP 2019 will be the next impressive edition of the Congress which is the outcome of the enduring collaboration of Cancer Research UK (CRUK), the European Society for Medical Oncology (ESMO) and Unicancer.
Fast Facts: MAP 2019
- Expecting over 400 participants
- New: 1 workshop
- No parallel sessions
- More than 35 key opinion leaders
- Excellent networking opportunities
How can I participate in MAP 2019?
At ESMO we are committed to providing our industry partners with a variety of solutions to facilitate their presence at our congress.
For sponsorship information and a prospectus please contact:
Head of Strategic Partnerships
We look forward to hearing from you!
Who has already signed up?
The MAP Organising partners gratefully acknowledge the valuable contribution the following organisations have made to the MAP 2019. (As of August 2019):
Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise includes both marketed products and clinical development compounds, which reflect the company’s approach to research: prioritizing targets and pathways with the potential to impact the way that cancer is treated.
F. Hoffmann-La Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
- Stand: 4
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Follow us on Twitter https://twitter.com/amgen.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com.
Datar Cancer Genetics Limited
Datar Cancer Genetics Limited is one of the fully integrated Molecular analysis facilities with having customer base in the US, Canada, UK, Germany and the Middle East.
We are accredited by the ISO 9001:2015, NABL15189: 2012 and the CAP and ISO 27001.
- Stand: 5
Janssen Research & Development, LLC
At Janssen, we’re creating a future where disease is a thing of the past. We’re working tirelessly for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
For more than fifty years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit our website.
Novartis is reimagining medicine to improve and extend people’s lives. We use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally.
Adaptive Biotechnologies is a pioneer in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.
- Stand: 8
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Educational Grant Supporter
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. We are focused on helping patients in disease areas including oncology, cardiovascular, immunoscience and fibrosis. Each day, our employees work together for patients.
For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, MSD continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.